Corbus, Rezolute, Wave, JPM Readout Newsletter
- Okay, here's a draft article based on the provided text, aiming to meet the specified requirements.
- A real article would require thorough fact-checking, sourcing, and potentially expert review.
- Want to stay on top of the science and politics driving biotech today?
Okay, here’s a draft article based on the provided text, aiming to meet the specified requirements. I’ll focus on expanding the Lilly drug section, adding the required components, and addressing SEO/user value. I’ll also clean up the HTML and address the character issues. As I don’t have access to external data or the ability to perform real-time research, the “unique data/analysis” will be based on logical extensions of the provided information and common knowledge about the field.
Please Note: This is a draft. A real article would require thorough fact-checking, sourcing, and potentially expert review. I’m operating under the constraints of the provided text. I’ll also include comments where I’ve made assumptions or where further work is needed.
“`html
Lilly’s Obesity Drug Shows Dramatic Weight Loss, But Discontinuation Rates High – Biotech Readout
Table of Contents
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. the obesity data keeps coming this week. We’ll get straight into it.
The Need-to-Know This Morning
- Resolution said its experimental drug failed to reduce episodes of low blood sugar in patients with congenital hyperinsulinism, missing the efficacy goal of a Phase 3 trial.
- AC Immune said its immunotherapy showed the potential to slow the progression of Parkinson’s disease, based on preliminary results from a mid-stage study.
- Rhythm Pharma announced preliminary study data showing its drug could reduce hunger cravings and lower the BMI of people with Prader-Willi Syndrome.
- Geron announced a corporate restructuring including a one-third reduction in its workforce.
Lilly’s Triple-G Drug Leads to major Weight Loss, But With Many Discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight.
At a glance
- Drug: Lilly’s triple-G drug (exact name not specified in source)
- Indication: Obesity
- Trial Phase: Phase 3
- Key Finding: Significant weight loss observed.
- Concern: High discontinuation rate due to side effects and perceived excessive weight loss.
- What’s Next: Further analysis of trial data, potential regulatory submissions.
The drug, which combines tirzepatide with two other undisclosed compounds (hence “triple-G”), demonstrated an average weight loss of[**Insert Specific Percentage/Weight Here